stockrow
Saturday 7 November 2026
Export CRBU’s income statement to Excel — free account
Caribou Biosciences, Inc.
CRBU Healthcare Biotechnology
Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024.
- Revenue
- −26.9%
- EPS
- +16.7%
- Free cash flow
- +84.8%
Quarter to September 2026, against a year earlier
0.44
0.03
+7.32%
Follow CRBU
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 6 | 12 | 10 | 14 | 34 | 10 | 11 | 9 | +11.6% | 24 | 23 | 31 | +40.4% | |
| Gross margin, % | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | (31) | (36) | (67) | (99) | (102) | (149) | (149) | (103) | +29.9% | ||||||
| EBT margin, % | — | — | — | (535.04) | (292.27) | (693.92) | (717.28) | (295.49) | (1,492.04) | (1,332.33) | (1,090.82) | (797.3) pt | ||||||
| Net income | — | 0 | — | (23) | (34) | (67) | (99) | (102) | (149) | (148) | (102) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.69 | 1.45 | 0.30 | 0.23 | 0.47 | 0.11 | 0.12 | 0.09 | (25.4%) | |||||
| Earnings | — | — | — | (2.80) | (4.01) | (2.11) | (1.64) | (1.38) | (1.65) | (1.59) | (1.03) | (9.0%) | ||||||
| Cash flow | — | — | — | (3.82) | (3.89) | (1.03) | (1.50) | (1.26) | (1.53) | (1.19) | (0.87) | (17.7%) | ||||||
| Capex | — | — | — | (0.11) | (0.04) | (0.07) | (0.11) | (0.16) | (0.05) | (0.01) | 0.00 | (28.1%) | ||||||
| Free cash flow | — | — | — | (3.93) | (3.92) | (1.09) | (1.60) | (1.42) | (1.58) | (1.20) | (0.87) | (17.9%) | ||||||
| Book value | — | — | — | 0.00 | 2.09 | 12.25 | 4.95 | 4.99 | 2.80 | 1.31 | 0.71 | n/m | ||||||
| Shares, m | — | — | — | 8 | 9 | 32 | 61 | 74 | 90 | 93 | 99 | +49.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | 13.15 | 13.15 | 49.78 | 29.02 | 11.92 | 14.37 | 13.31 | 5.01 | 20.7 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 1.23 | 1.34 | 1.12 | 0.57 | 1.22 | 0.62 | 0.8 | ||||||
| EV/Sales | — | — | — | 2.98 | 2.98 | 10.62 | 11.14 | 2.39 | (6.60) | 0.82 | (5.03) | 3.5 | ||||||
| EV/FCF | — | — | — | (2.82) | (2.82) | (2.94) | (1.58) | (0.78) | 0.46 | (0.08) | 0.36 | (1.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (32) | (33) | (33) | (91) | (93) | (138) | (111) | (93) | +23.0% | |||||
| Capex | — | — | — | (1) | 0 | (2) | (6) | (12) | (5) | (1) | (37) | +7.4% | ||||||
| Free cash flow | — | — | — | (33) | (34) | (35) | (97) | (105) | (143) | (112) | (93) | +22.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 47 | 12 | 365 | 232 | 311 | 189 | 120 | 80 | +16.9% | |||||
| Net debt | — | — | — | (41) | (16) | (376) | (248) | (329) | (210) | (139) | (95) | +22.6% | ||||||
| Shareholders’ equity | — | — | — | — | 18 | 388 | 301 | 368 | 253 | 122 | 77 | +46.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (190.36) | (27.98) | (24.36) | (25.33) | (40.00) | (60.62) | (64.44) | (60.6) pt | |||||
| ROIC | — | — | — | 0.00 | (1,168.00) | (349.05) | (124.98) | (183.29) | (239.87) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 293.36 | 429.55 | (36.73) | (28.87) | (30.50) | (47.99) | (78.97) | (93.80) | (372.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 97 | 137 | 158 | 147 | 97 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.10 | 0.10 | 0.22 | 0.07 | 0.12 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Caribou Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $46.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| MREO Mereo BioPharma Group plc - Sponsored ADR | $44.8M | — (loss-making) | — (loss-making) | — | n/m | +21.02% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IBIO iBio, Inc. | $44.4M | — (loss-making) | — (loss-making) | +100.00% (above 0%: growing) | n/m | −35.33% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CRBU Caribou Biosciences, Inc. | $44.2M | — (loss-making) | — (loss-making) | −26.89% (below 0%: shrinking) | n/m | +84.78% (above 0%: growing) | 100.00% | (1,720.10%) | |
| BMEA Biomea Fusion, Inc. | $42.6M | — (loss-making) | — | — | n/m | +47.80% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ATHE Alterity Therapeutics Limited - Sponsored ADR | $42.4M | — (loss-making) | — | — | 0.00% | −84.83% (below 0%: shrinking) | 0.00% | — | Compare |
| GANX Gain Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | +27.78% (above 0%: growing) | n/m | +8.22% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SER Serina Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | +2,500.00% (above 0%: growing) | n/m | −76.82% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SGMOQ Sangamo Therapeutics, Inc. | $41.9M | — (loss-making) | — (loss-making) | −77.60% (below 0%: shrinking) | n/m | +26.21% (above 0%: growing) | 100.00% | (2,215.40%) | Compare |
| Median of peers | $42.5M | — | — | +100.00% | — | −7.63% | 50.00% | 0.00% |
Pay and ownership Proxy statement filed 24 April 2026
Ownership
Directors and executive officers, together
8.54%
Rachel Haurwitz, Ph.D.
5.28%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement